SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
9 references·3 citing·48 second hop
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model (2007)Cost-effectiveness of omalizumab in adult…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Systematic Overview of Cost-Utility Assessments in Oncology (2000)Systematic Overview of Cost-U…Integrating Patient Preferences Into Health Outcomes Assessment (1998)Integrating Patient Preferenc…Multiattribute Utility Function for a Comprehensive Health Status Classification System (1996)Multiattribute Utility Functi…Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life (1993)Relationship between psychome…Markov Models in Medical Decision Making (1993)Markov Models in Medical Deci…Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia (1991)Cost Effectiveness of Prophyl…Health and medicine (1990)Health and medicineThe Markov Process in Medical Prognosis (1983)The Markov Process in Medical…Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations (2018)Cost-Effectiveness of Biologi…Cost-effectiveness of asthma therapy: a comprehensive review (2014)Cost-effectiveness of asthma …The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective (2010)The costs and consequences of…EuroQol - a new facility for the measurement of health-related quality of life (1990)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Health Care Economic Analyses and Value-Based Medicine (2003)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)Health Utilities Using the EQ-5D in Studies of Cancer (2007)Cost-Effectiveness in Health and Medicine (1996)Bias in published cost effectiveness studies: systematic review (2006)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Measuring Health-Related Quality of Life (1993)Decisions with Multiple Objectives: Preferences and Value Tradeoffs. (1994)Determining Clinically Important Differences in Health Status Measures (1999)The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies (2001)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Theory of games and economic behavior (2019)Measurement of health state utilities for economic appraisal (1986)Quality of life and pharmacoeconomics in clinical trials (1996)Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index (1998)A comparative review of four preference-weighted measures of health-related quality of life (2003)Modelling SF-6D health state preference data using a nonparametric Bayesian method (2006)The Framing of Decisions and the Psychology of Choice (1981)Measuring Functioning and Well-Being: The Medical Outcomes Study Approach (1992)Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications (1998)A Review of the Use of Health Status Measures in Economic Evaluation (1999)Feasibility, validity and test–retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off (1999)XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. In a letter to Francis Baily, Esq. F. R. S. &c (1825)A Population Study. (1975)A convenient approximation of life expectancy (the “DEALE”) (1982)The Beaver Dam Health Outcomes study (1993)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 (2012)Whose Utilities for Decision Analysis? (1990)Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems (1993)The standard gamble method: what is being measured and how it is interpreted. (1994)EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)Clinical decision analysis (2005)The General Theory of Employment, Interest and Money. (1936)The Civic Culture (1963)Policing the Crisis (1978)Cost effectiveness analysis in health care: contraindications (2002)Science, Reform, and Politics in Victorian Britain (2002)Science, reform, and politics in Victorian Britain: the Social Science Association, 1857-1886 (2003)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)An Introduction to Markov Modelling for Economic Evaluation (1998)Handling Uncertainty in Cost-Effectiveness Models (2000)Review of guidelines for good practice in decision-analytic modelling in health technology assessment (2004)
this work references cited by second hop

References

  • 1993Markov Models in Medical Decision Making2,411 cited
  • 1983The Markov Process in Medical Prognosis957 cited
  • 1996Multiattribute Utility Function for a Comprehensive Health Status Classification System900 cited
  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2000Systematic Overview of Cost-Utility Assessments in Oncology296 cited
  • 1998Integrating Patient Preferences Into Health Outcomes Assessment225 cited
  • 1991Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia204 cited
  • 1993Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life195 cited
  • 1990Health and medicine177 cited

Cited by

  • 2018Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations93 cited
  • 2010The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective81 cited
  • 2014Cost-effectiveness of asthma therapy: a comprehensive review74 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work